DaltonTx

United Kingdom - London

• 23/09/2025
• Seed
• $5,402,820

At DaltonTx, we are redefining how technology powers drug discovery — creating the intelligence engine behind tomorrow’s medicines.

Our adaptive, AI-enabled platforms give pharma, biotech, and CROs the intelligence backbone modern R&D cannot move forward without. Purpose-built for small molecules and biologics, our technology integrates seamlessly into scientific workflows, learns from every experiment, and accelerates the path from idea to medicine.

Unlike traditional project-based models, DaltonTx provides lasting capability: collaborative systems that combine machine learning, software engineering, and deep drug discovery expertise. The result is technology that learns from every scientist, model, and experiment — guiding better decisions, evolving with your science, and helping you deliver breakthrough therapies to patients faster.

Founded by scientists for scientists, DaltonTx brings together decades of real-world experience in drug discovery, software engineering, and AI. The team — Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE — has built pioneering AI discovery platforms at AstraZeneca and Exscientia, while also drawing on world-leading academic research from the University of Oxford. This unique combination of industry execution and academic excellence positions DaltonTx at the forefront of AI-enabled drug discovery.

Related People

Garry PairaudeauFounder

United Kingdom - ND

Throughout my career I have been passionate about technology, innovation and how to transform organisations to discover new medicines in the most effective way.
An Executive leader with 30 years experience in drug discovery across both large pharma at AstraZeneca and Biotech. Proven track record in building high performing teams and organisations across trans-national boundaries, ability to bring clarity and create energy, drive and purpose across an organisation.
Substantive experience of leading digital transformation; implementing state of the art computational platforms, AI and Automation into multiple drug discovery organisations.

LinkedIn https://www.linkedin.com/in/garry-pairaudeau-b04b1311/